Antithrombin III and Hepatocellular Carcinoma

Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.

Facebook Linkedin Weibo

Thromb Haemost 1989; 62(02): 817
DOI: 10.1055/s-0038-1646913

Letters to the Editor

Schattauer GmbH Stuttgart

J J Lefrére

^*Institut National de Transfusion Sanguine 6, rue Alexandre-Cabanel 75015 Paris, France

,

J Conard

^**Laboratoire Central d’hématologie, Hâpital de l’Hâtel-Dieu Paris, France

,

J Lerable

^*Institut National de Transfusion Sanguine 6, rue Alexandre-Cabanel 75015 Paris, France

,

M Samama

^**Laboratoire Central d’hématologie, Hâpital de l’Hâtel-Dieu Paris, France

Weitere Informationen

Publikationsverlauf

Received 13. März 1989

Accepted after revision 04. April 1989

Publikationsdatum:
30. Juni 2018 (online)

References
1 Leone G, DeStefano V, Garufi C, Ferrelli R, Cassano A, Grieco A. Antithrombin III in patients with hepatocellular carcinoma. Thromb Haemostas 1987; 58 (04) 1093

MissingFormLabel
PubMed Suche in Google Scholar
2 Lefrère JJ, Gozin D, Bettan L. Proaccelerin and prothrombin assays for detection of hepatocellular carcinoma. Hepatology 1987; 7 (02) 414

MissingFormLabel
PubMed Suche in Google Scholar
3 Liebman HA, Furie BC, Tong MJ. et al Des-gammacarboxy (as normal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-1431

MissingFormLabel
Crossref PubMed Suche in Google Scholar